North America Monoclonal Antibodies (mAbs) Market Outlook 2022: Big Things are Happening

HTF Market Intelligence released a new research report of 102 pages on title 'North America Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity’ with detailed analysis, forecast and strategies. The study covers key regions that includes North America and important players such as Abbott Laboratories, AbbVie, Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Mylan N.V, Norvatis AG, Pfizer, Sanofi S.A.

Request a sample report @ https://www.htfmarketreport.com/sample-report/3765818-north-america-monoclonal-antibodies-mabs-market-2020-2030-by-source-human-humanized-chimeric-murine-category-branded-biosimilar-production-type-in-vitro-in-vivo-application-cancer-autoimmune-inflammatory-end-user-and-country

Summary
North America monoclonal antibodies market is projected to grow by 10.4% annually in the forecast period and reach $133.4 billion by 2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
Highlighted with 24 tables and 48 figures, this 102-page report “North America Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country.

Based on Source, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Human
• Humanized
• Chimeric
• Murine

Based on Category, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Branded mAbs
• Biosimilar mAbs

Based on Production Type, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• In Vitro Production
• In Vivo Production

Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Ovarian Cancer
o Other Cancer Types
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Other Applications

By End User, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Hospitals
• Research Institutes
• Other End Users

Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.

Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/3765818-north-america-monoclonal-antibodies-mabs-market-2020-2030-by-source-human-humanized-chimeric-murine-category-branded-biosimilar-production-type-in-vitro-in-vivo-application-cancer-autoimmune-inflammatory-end-user-and-country

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=3765818

Contact US:
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com
Connect with us at LinkedIn | Facebook | Twitter

About Author:
HTF Market Intelligence consulting is uniquely positioned empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist in decision making.

This release was published on openPR.